p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy

One hundred and thirty-eight stage II and III colorectal cancer patients were included to evaluate the prognostic significance of genetic markers (including mutations of the p53, K- ras genes, and microsatellite instability) on the response to 5-fluorouracil (FU)-based post-operative adjuvant therap...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2004-07, Vol.210 (1), p.101-109
Main Authors: Tang, Reiping, Wang, Jeng-Yi, Fan, Chung-Wei, Tsao, Kuo-Chien, Chen, Hong-Hua, Wu, Chi-Ming, Chen, Jinn-Shiun, Changchien, Chung Rong, Hsieh, Ling-Ling
Format: Article
Language:English
Subjects:
Antimetabolites, Antineoplastic - therapeutic use
Cancer therapies
Chemotherapy
Chemotherapy, Adjuvant
Colorectal cancer
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Colorectal Neoplasms - pathology
Confidence intervals
Deoxyribonucleic acid
Disease
DNA
DNA, Neoplasm - genetics
Family medical history
Female
Fluorouracil - therapeutic use
Gene Expression Regulation, Neoplastic
Genes, p53
Genes, ras
Genetic Markers
Genetic testing
Humans
K-ras mutation
Male
Medical prognosis
Microsatellite Repeats
Middle Aged
Mutation
Neoplasm Staging
p53 mutation
Post-operative adjuvant therapy
Postoperative Care
Prognosis
Radiation therapy
Studies
Survival Rate
Time Factors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:One hundred and thirty-eight stage II and III colorectal cancer patients were included to evaluate the prognostic significance of genetic markers (including mutations of the p53, K- ras genes, and microsatellite instability) on the response to 5-fluorouracil (FU)-based post-operative adjuvant therapies (PAT). When stratified by PAT and adjusting for other prognostic variables, presence of p53 mutation was associated with a poor outcome (hazard ratio (HR)=3.1, 95% confidence interval (CI), 0.9–11.0) among patients without PAT. Our data confirmed that p53 mutation is an independent pre-treatment factor in stage II and III colorectal cancer after curative resection.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2004.01.006